Navigation Links
Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment
Date:5/17/2013

FARMINGTON, Conn., May 17, 2013 /PRNewswire-iReach/ -- The escalation of new biological drugs, including antibodies and recombinant proteins, is placing renewed emphasis on alternate delivery technologies. Alternate delivery technologies are on the rise as a number of factors are converging to create both risk and opportunity for pharmaceutical makers and their delivery device partners. These include new classes of drugs for previously refractory conditions, the growing trend toward self-administration for chronic diseases, shifting patient demographics in industrial countries, caregiver safety legislation, and continued pressure to control healthcare costs.

(Photo: http://photos.prnewswire.com/prnh/20130517/CG15876)

These factors are giving rise to a new generation of sophisticated, application-specific injection, inhalation and transdermal drug products designed to satisfy caregiver and patient preferences while addressing managed care initiatives and the formulation limitations of new classes of therapeutic drugs. Because of their ability to safely and reliably satisfy treatment protocols and compliance goals, non-oral drug delivery products will have a significant impact on the future of drug self-administration.

The new Drug Self-Administration to 2018: Drug Products, Indications, Markets and Forecasts report is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the drug delivery sector.

Request a free sample from Global Information's market research portal to learn more or easily order your copy online here.

For more recently released reports from Greystone Research Associates please visit the following links:

Transdermal Drug Patches to 2018: Products, Indications, Markets and Forecasts

Published March, 2013

Injectable Drug Delivery to 2018: Drugs, Devices, Targets, Therapeutics and Forecasts

Published March, 2013

Autoinjectors to 2018: Devices, Therapeutics, Market, Strategies and Prospects

Published March, 2013

About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 400 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 30 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

About Greystone Research Associates As life science consultants, Greystone Research Associates focuses on one industry and one objective - providing management guidance in an increasingly dynamic medical technology marketplace. The value Greystone Research Associates provides to their clients and subscribers is best illustrated by their ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process. Greystone Research Associates delivers their knowledge franchise through concise market appraisals, company analysis, and technology reports. Their publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge necessary to refine and execute their marketing plans and achieve their financial targets.

Media Contact:  Joe Malley Global Information, Inc., 1-860-674-8796, Press@gii.co.jp

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Global Information, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
2. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
3. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
4. Access Pharmaceuticals Reports First Quarter Results
5. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
6. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
7. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
8. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
9. Auxilium Pharmaceuticals, Inc. To Present At The UBS Global Health Care Conference
10. Savient Pharmaceuticals Reports First Quarter 2013 Financial Results
11. The Law Offices of Marc S. Henzel Announces Class Action Lawsuit Against Aveo Pharmaceuticals, Inc. and Certain Officers -- (Nasdaq: AVEO) was filed on behalf of stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... 30, 2016 LifeScienceIndustryResearch.com adds ... research report with comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:5/27/2016)... LONDON , May 27, 2016 ... an innovative biopharma company focused on the highly ... built a substantial pipeline of potential first-in-class or ... which are in development with strategic partners. HCM,s ... the fast-growing domestic market. We expect progress of ...
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of ... Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who ... this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program ...
(Date:5/27/2016)... ... 27, 2016 , ... With over 60 percent of acute stroke survivors being ... product to aid in the rehabilitation process has steadily increased. Ekso Bionics had been ... hemiplegia due to stroke. , Ekso Bionics has now received clearance from the U.S. ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... help educate the many who are unaware of the plight of aphasia. In ... run within the “Stroke Awareness” campaign. , The link between stroke and aphasia ...
(Date:5/27/2016)... ... , ... Aimed at nurses and employees in the health care world, this ... the nursing and health care industry. It also provides insight to the developing trends ... , As the nursing industry is coming out of one of the biggest recessions ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
Breaking Medicine News(10 mins):